![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Hybio Pharmaceutical Co., Ltd. Shenzhen Cn, based in China, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Leuprorelin, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2019-016 - Rev 00
This Chemical Type CEP, issued on April 23, 2020, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1442 associated with this CEP further emphasizes